Multiple myeloma (MM) is a genetically complex disease that evolves from pre-malignant
stages, such as monoclonal gammaopathy of undetermined significance and smouldering …

Genetic instability, which includes both numerical and structural chromosomal
abnormalities, is a hallmark of cancer. Whereas the structural chromosome rearrangements …

Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than
20,000 people annually in the United States. There has been a veritable revolution in this …

Objective To understand the role of the genetic changes and bone marrow
microenvironment on the development, progression, and staging of multiple myeloma (MM) …

Myeloma is a malignant proliferation of monoclonal plasma cells. Although morphologically
similar, several subtypes of the disease have been identified at the genetic and molecular …

PURPOSE The wide heterogeneity in multiple myeloma (MM) outcome is driven mainly by
cytogenetic abnormalities. The current definition of high-risk profile is restrictive and …

Multiple myeloma is an incurable plasma cell malignancy with only a 53% 5-year survival
rate. There is a critical need to find new multiple myeloma vulnerabilities and therapeutic …

Multiple myeloma is a plasma cell malignancy characterized by complex heterogeneous
cytogenetic abnormalities. The bone marrow microenvironment promotes multiple myeloma …

T-cell–mediated approaches have shown promise in myeloma treatment. However, there
are currently a limited number of specific myeloma antigens that can be targeted, and …

Drug resistance remains a major clinical challenge for cancer treatment. Multiple myeloma is
an incurable plasma cell cancer selectively localized in the bone marrow. The main cause of …